Collaboration Compound definition
Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).
Collaboration Compound means a Drug Candidate (and any Follow-On Compound with respect to such Drug Candidate) and/or a Future Program Compound (and any Follow-On Compound with respect to such Future Program Compound), as applicable.
Collaboration Compound means [ * ].
Examples of Collaboration Compound in a sentence
CombiChem shall maintain aliquots of any Collaboration Compound that has been synthesized by CombiChem.
Provided, however, that ADDEX must diligently develop such Collaboration Compounds as provided in 3.5 (however an additional year shall be added to the Time to Complete for commencing Phase I for the first Collaboration Compound pursued under this provision).
ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***].
After the Effective Date, GlobeImmune shall provide written notice to Celgene promptly after commencing any additional Development efforts for any Collaboration Compound.
Notwithstanding anything to the contrary in this Section 9.7.3, GlobeImmune’s clinical trial sites shall have the right to publish summaries of results of Clinical Trials conducted by GlobeImmune at such site with respect to a Licensed Product incorporating a Collaboration Compound to the extent required under the applicable agreement(s) between GlobeImmune and such clinical trial sites.
More Definitions of Collaboration Compound
Collaboration Compound means any of Lead Compound and/or Back-Up Compounds.
Collaboration Compound means any molecule that (a) has a molecular weight less than or equal to [ * ]; (b) has the ability to inhibit, activate or otherwise modulate the activity of a Mammalian Target (other than a Confirmed Target) or its encoded protein; and (c) such ability is identified by or on behalf of BMS or its Affiliate or sublicensee through the use to any material extent of a Mammalian Target (other than a Confirmed Target) or any information relating to a Mammalian Target (other than a Confirmed Target) developed by or on behalf of BMS or its Affiliate or sublicensee by material use of such Mammalian Target, the DNA sequence relating thereto, or any other Research Results disclosed to BMS hereunder that (i) directly relate to such Mammalian Target (other than a Confirmed Target) or the Target to which such Mammalian Target is related, and (ii) Remain Confidential at the time of such use, provided that the foregoing definition is subject to the limitations in Section 4.15.
Collaboration Compound means any ADC that is generated within the Collaboration Program, as well as the antibodies incorporated in the ADC.
Collaboration Compound means: (a) Lead Compounds; (b) Development Candidates; or (c) any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, co-crystals, polymorphs, ester, or prodrug of the compounds set forth in clause (a) or (b) of this definition.
Collaboration Compound means ▇▇▇▇▇▇▇▇▇’▇ proprietary compound designated by ▇▇▇▇▇▇▇▇▇ on the Effective Date as “HMPL-504,” as more fully described in Schedule 1.19 and as improved or modified in connection with this Agreement, [**].
Collaboration Compound means, except as provided below, any composition of matter that (or, in the case of prodrugs, an active metabolite of which):
(a) demonstrates in vitro activity as
(i) an Agonist with [***] as determined by one of the Agonist Assays specified in Appendix B; or
(ii) an Antagonist with [***] as determined by one of the Antagonist Assays specified in Appendix B; or
(iii) a Negative Allosteric Modulator with [***] or less as determined by one of the NAM Assays specified in Appendix B or
(iv) a Positive Allosteric Modulator with [***] or less as determined by one of the ▇▇▇ Assays specified in Appendix B; and
(b) either
(i) first discovered, identified, synthesized or acquired by ADDEX or its Affiliate (in case ADDEX has extended its rights pursuant to Article 8.2) or on behalf of ADDEX or said Affiliate by a Third Party contractor having no property right in such composition of matter prior to the end of the Research Period, and is recognized by either Party to meet the condition of (a) hereof prior to the expiration of [***] months following the end of the Research Period; or
(ii) is first discovered, identified, synthesized or acquired by OMP or its Affiliate (in case OMP has extended its rights pursuant to Article 8.2) or on behalf of OMP or said Affiliate by a Third Party contractor having no property right in such composition of matter during the Research Period and is recognized by either Party to meet the condition of (a) hereof prior to the expiration of [***] months following the end of the Research Period; or
(iii) is Jointly Invented by the parties described in subsection (i) and (ii) above during the Research Period and is recognized by either Party to meet the condition of (a) hereof prior to the expiration of [***] months following the end of the Research Period; or
(c) [***] any issued claim of any unexpired Program Patent [***], or in a claim of a pending application for such a Program Patent (including such a claim of a PCT application [***]) to the extent that said claim is [***] and is [***], and as to which claim at least [***], whether or not [***]. Collaboration Compounds shall not include any composition of matter that as of the Effective Date a) [***]; b) [***]; or c) [***]. As used in this Article 1.14, the term “acquired” shall include the acquisition of absolute or contingent rights, such as rights under an option.
Collaboration Compound shall have the meaning set forth in Section 1.4 of the Collaboration Agreement.